Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMDNASDAQ:CTORNASDAQ:CYCCNASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.89+15.5%$0.84$0.52▼$8.95$14.33M2.28306,114 shs90,493 shsCTORCitius Oncology$0.64-4.3%$0.83$0.55▼$4.42$45.87M-0.191.21 million shs54,239 shsCYCCCyclacel Pharmaceuticals$0.23-0.5%$0.28$0.17▼$4.00$47.48M0.151.22 million shs372,917 shsPRLDPrelude Therapeutics$0.86-2.4%$0.75$0.61▼$6.80$48.64M1.35267,228 shs114,977 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed+4.24%+6.10%-11.66%-30.60%-85.60%CTORCitius Oncology+1.52%+3.72%-5.63%-47.24%+66,999,900.00%CYCCCyclacel Pharmaceuticals+2.04%+6.38%-28.95%-34.23%-87.14%PRLDPrelude Therapeutics-5.91%+14.70%+22.67%-22.53%-77.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFMDAffimed3.892 of 5 stars3.43.00.04.32.50.01.3CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.9595 of 5 stars3.33.00.00.00.62.50.6PRLDPrelude Therapeutics1.7607 of 5 stars3.20.00.00.00.65.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.80Moderate Buy$13.501,416.85% UpsideCTORCitius Oncology 3.00Buy$3.00368.02% UpsideCYCCCyclacel Pharmaceuticals 2.50Moderate Buy$11.004,703.49% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00364.25% UpsideCurrent Analyst Ratings BreakdownLatest AFMD, PRLD, CTOR, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K16.34N/AN/A$4.19 per share0.21CTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/ACYCCCyclacel Pharmaceuticals$74K641.62N/AN/A$0.57 per share0.40PRLDPrelude Therapeutics$7M6.95N/AN/A$4.32 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%6/11/2025 (Estimated)CTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%5/9/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$3.50N/A∞N/A-18,150.00%-1,901.11%-188.23%5/13/2025 (Estimated)PRLDPrelude Therapeutics-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%5/6/2025 (Estimated)Latest AFMD, PRLD, CTOR, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29N/AN/AN/A$0.03 millionN/A5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.48N/AN/AN/AN/AN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04-$0.33$0.01 million$0.01 million3/10/2025Q4 2024PRLDPrelude Therapeutics-$0.49-$0.38+$0.11-$0.38N/A$4.00 million2/14/2025N/ACTORCitius OncologyN/A-$0.09N/A-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ALatest AFMD, PRLD, CTOR, and CYCC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2025CYCCCyclacel Pharmaceuticals$0.154/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93CTORCitius Oncology0.080.340.08CYCCCyclacel PharmaceuticalsN/A0.770.77PRLDPrelude TherapeuticsN/A7.047.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%CTORCitius Oncology70.52%CYCCCyclacel Pharmaceuticals23.58%PRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%CTORCitius Oncology4.57%CYCCCyclacel Pharmaceuticals68.00%PRLDPrelude Therapeutics62.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/ACYCCCyclacel Pharmaceuticals14207.34 million4.78 millionOptionablePRLDPrelude Therapeutics12056.45 million20.47 millionOptionableAFMD, PRLD, CTOR, and CYCC HeadlinesRecent News About These CompaniesPrelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should KnowApril 10, 2025 | zacks.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comPrelude Therapeutics sees cash runway into 2Q26March 10, 2025 | markets.businessinsider.comPrelude Therapeutics Reports Positive Clinical Results for SMARCA2 Degrader PRT3789 in Phase 1 Trials and Provides Financial UpdateMarch 10, 2025 | quiverquant.comPrelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025March 10, 2025 | globenewswire.comPrelude Therapeutics to Present at Barclays Global Healthcare ConferenceMarch 6, 2025 | msn.comPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comInsider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires 10,000 Shares of StockJanuary 3, 2025 | insidertrades.comAndrew Combs Acquires 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockDecember 27, 2024 | insidertrades.comPrelude Therapeutics Inc (PRLD) Stock Trading RecapDecember 24, 2024 | bovnews.comKrishna Vaddi Bought 4.9% More Shares In Prelude TherapeuticsDecember 22, 2024 | uk.finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim Buys 25,000 SharesDecember 21, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Short Sellers Wrong About These 3 Semiconductor Stocks?By Leo Miller | April 4, 2025View Are Short Sellers Wrong About These 3 Semiconductor Stocks?Why NVIDIA Stock Could Soar Despite Wall Street DowngradesBy Thomas Hughes | April 14, 2025View Why NVIDIA Stock Could Soar Despite Wall Street Downgrades2 Defensive Sectors to Protect Your Portfolio During a RecessionBy Ryan Hasson | April 7, 2025View 2 Defensive Sectors to Protect Your Portfolio During a RecessionThe 5 Most Oversold Stocks on the Market Are… By Thomas Hughes | March 28, 2025View The 5 Most Oversold Stocks on the Market Are… Who Led Buybacks to End 2024? Hint: It Wasn’t Big TechBy Leo Miller | April 8, 2025View Who Led Buybacks to End 2024? Hint: It Wasn’t Big TechAFMD, PRLD, CTOR, and CYCC Company DescriptionsAffimed NASDAQ:AFMD$0.89 +0.12 (+15.54%) As of 04:00 PM EasternAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Citius Oncology NASDAQ:CTOR$0.64 -0.03 (-4.33%) As of 04:00 PM EasternCitius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Cyclacel Pharmaceuticals NASDAQ:CYCC$0.23 0.00 (-0.52%) As of 04:00 PM EasternCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Prelude Therapeutics NASDAQ:PRLD$0.86 -0.02 (-2.45%) As of 04:00 PM EasternPrelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
